Polynovo Ltd
ASX:PNV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Polynovo Ltd
Change in Working Capital
Polynovo Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Polynovo Ltd
ASX:PNV
|
Change in Working Capital
AU$2.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
28%
|
CAGR 10-Years
11%
|
|
|
Nanosonics Ltd
ASX:NAN
|
Change in Working Capital
AU$6.3m
|
CAGR 3-Years
146%
|
CAGR 5-Years
52%
|
CAGR 10-Years
17%
|
|
|
SDI Ltd
ASX:SDI
|
Change in Working Capital
AU$7k
|
CAGR 3-Years
-83%
|
CAGR 5-Years
-71%
|
CAGR 10-Years
N/A
|
|
|
Anteris Technologies Ltd
ASX:AVR
|
Change in Working Capital
AU$6.3m
|
CAGR 3-Years
50%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Ansell Ltd
ASX:ANN
|
Change in Working Capital
$6.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
L
|
Lumos Diagnostics Holdings Ltd
ASX:LDX
|
Change in Working Capital
$1.2m
|
CAGR 3-Years
315%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Polynovo Ltd
Glance View
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
See Also
What is Polynovo Ltd's Change in Working Capital?
Change in Working Capital
2.5m
AUD
Based on the financial report for Dec 31, 2025, Polynovo Ltd's Change in Working Capital amounts to 2.5m AUD.
What is Polynovo Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
11%
Over the last year, the Change in Working Capital growth was 319%.
